Welcome to our dedicated page for Opus Genetics SEC filings (Ticker: IRD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Opus Genetics, Inc. (Nasdaq: IRD) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K and other filings that document material events, financing transactions, and clinical or regulatory milestones. Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases (IRDs) and small-molecule therapies for other ophthalmic disorders, and its filings offer detailed insight into these activities.
Through its Form 8-K filings, the company reports material agreements and financings, such as securities purchase agreements for registered direct offerings of common stock and pre-funded warrants, including the use of proceeds to advance its LCA5 and BEST1 gene therapy clinical programs. These filings may also describe the terms of pre-funded warrants, closing conditions, and related legal opinions. Additional 8-Ks furnish press releases that announce financial results, cash position, and collaboration revenue, providing context on how Opus Genetics funds its research and development operations.
Regulation FD disclosures and other events reported in SEC filings frequently cover clinical and regulatory developments, including positive data from the OPGx-LCA5 Phase 1/2 trial, enrollment updates, and outcomes of FDA interactions such as Regenerative Medicine Advanced Therapy (RMAT) meetings. The company also uses 8-Ks to disclose inducement equity awards granted under its 2021 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
On Stock Titan, these filings are paired with AI-powered summaries that help explain the key points of each document, from financing structures to trial design details. Users can review Opus Genetics’ quarterly and annual reports when available, as well as current reports and exhibits, to better understand its ophthalmic gene therapy pipeline, collaboration arrangements, and capital structure as described in its official SEC submissions.
Opus Genetics, Inc. director and President Benjamin R. Yerxa reported an open-market sale of 7,470 shares of common stock at a weighted average price of $5.2371 per share. The shares were sold automatically by the company to satisfy tax withholding obligations from a restricted stock unit vesting event and were not a discretionary trade. After this transaction, Yerxa holds 711,535 shares of Opus Genetics common stock directly.
Opus Genetics, Inc. Chief Operating Officer Joseph K. Schachle reported an automatic share sale tied to tax withholding. On this transaction, 4,697 shares of common stock were sold at $5.2202 per share to satisfy tax obligations arising from a restricted stock unit vesting and settlement event. The filing notes this was not a discretionary trade by the executive. After the sale, Schachle directly holds 296,084 shares of Opus Genetics common stock.
Opus Genetics, Inc. executive Amy Zaremba Rabourn reported an automatic sale of 1,641 shares of common stock at a weighted average price of $5.204 per share. The company executed the sale to cover tax withholding obligations from a restricted stock unit vesting event.
This was not a discretionary trade by the officer. After the sale, she still directly holds 188,671 shares, so the transaction represents a small portion of her total reported holdings.
Opus Genetics, Inc. Chief Executive Officer George Magrath reported an automatic disposition of common stock tied to a tax event. On April 23, 2026, 9,511 shares of common stock were sold at $5.22 per share to satisfy tax withholding obligations from a restricted stock unit vesting and settlement. According to the filing, this did not represent a discretionary trade by the executive. After this transaction, Magrath directly holds 1,741,344 shares of Opus Genetics common stock.
Opus Genetics, Inc. Chief Scientific & Dev. Officer Jayagopal Ashwath reported an automatic sale of common stock tied to tax obligations. On this Form 4, 7,542 shares were sold in an open-market transaction at a weighted average price of $5.1917 per share.
According to the footnotes, the sale was executed automatically by the company to satisfy tax withholding arising from a restricted stock unit vesting and settlement, and was not a discretionary trade. After the sale, Ashwath directly owns 509,233 shares of Opus Genetics common stock.
Opus Genetics, Inc. Chief Financial Officer Robert E. Gagnon reported an automatic sale of 7,842 shares of Common Stock on April 23, 2026. The sale was executed at a weighted average price of $5.1846 per share to satisfy tax withholding obligations arising from the vesting and settlement of a restricted stock unit award, and was not a discretionary trade. After this transaction, Gagnon directly holds 592,158 shares of Opus Genetics common stock. The shares were sold in multiple trades at prices ranging from $5.1828 to $5.1901 per share.
Opus Genetics, Inc. entered into a senior secured note purchase agreement that allows issuance of up to $155 million in senior secured notes. Purchasers have committed to $105 million, with an additional $50 million uncommitted and available upon meeting conditions and milestones.
The initial tranche of $35 million was funded at par on April 21, 2026, with these notes maturing on April 21, 2033. The notes bear floating interest based on Term SOFR, subject to a floor, plus a margin, paid quarterly. They are secured by substantially all company and subsidiary assets and guaranteed by certain subsidiaries, with obligations subject to customary events of default.
IRD filed a Form 144 reporting a proposed sale of 15,625 shares of Common Stock. The filing lists the shares as from an RSU grant vesting and indicates a sale method through Raymond James & Associates on 04/23/2026 for cash. The notice also records a prior sale of 3,719 shares on 03/16/2026, with an associated amount of 19525.00.
IRD submits a Form 144 notice reporting the proposed sale of 30,227 shares of Common Stock issued upon an RSU grant vest on 04/23/2026 with cash as the planned consideration. The filing also records a prior sale of 24,438 shares by George N. Magrath on 03/16/2026.